Webinars
All Webinars
All Webinars

Recent

Optometrist Webinars

Conversations with a Referring Partner: ForeseeHome in Practice

Integrating ForeseeHome into the Practice Workflow

Managing Intermediate AMD - Part 1: Stages of AMD

Managing Intermediate AMD - Part 2: ForeseeHome AMD Monitoring Program

Managing Intermediate AMD - Part 3: Implementing ForeseeHome into Workflow

Introduction to the Notal Vision Diagnostic Clinic

Introduction to ForeseeHome® Patient Status Reports

Introduction to ForeseeHome® Metamorphopsia Maps & Alerts

COVID-19: Navigating practice and 'at-risk' patient pathways (Highlight Video)

COVID-19: Navigating practice and “at-risk” patient pathways

Barriers for timely detection of wet AMD and what we can do to overcome them

Early wet AMD detection: Impact on vision outcomes, challenges to detection, and a solution

Privacy Policy
Privacy Practices
Patents
Contact Us
NotalVision.com
ForeseeHome.com

FDA Indication for Use

The ForeseeHome is intended for use in the detection and characterization of central and paracentral metamorphopsia (visual distortion) in patients with age-related macular degeneration, as an aid in monitoring progression of disease factors causing metamorphopsia including but not limited to choroidal neovascularization (CNV). It is intended to be used at home for patients with stable fixation.

The ForeseeHome AMD Monitoring Program is only available by physician order and is intended to be used as an addition to regular eye exams.

The ForeseeHome AMD Monitoring Program is covered by Medicare, subject to its coverage requirements for the test, to assess patients with dry AMD who are at risk of developing wet AMD.

ForeseeHome is a registered trademark, and the ForeseeHome AMD Monitoring Program and logo and the Notal Vision logo are trademarks of Notal Vision.

© 2021 Notal Vision, Inc. All Rights Reserved.

View Webinars by Topic

ECP Portal Notal Vision Diagnostic Clinic COVID-19 AMD Management